Prime Medicine, Inc. (PRME) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Prime Medicine, Inc. is a biotechnology company developing Prime Editing technology for genetic medicines. The company is currently in the preclinical and early clinical stages, with no commercial product sales. Key programs include in vivo treatments for Wilson Disease and Alpha-1 Antitrypsin Deficiency (AATD), and a Phase 1/2 trial for Chronic Granulomatous Disease (CGD) in partnership with Bristol-Myers Squibb (BMS).
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0.86 million | $1.45 million |
| Net Loss | $(49.12) million | $(51.89) million |
| Net Loss Per Share | $(0.28) | $(0.40) |
| Operating Expenses | $51.51 million | $53.85 million |
| Cash & Short-Term Investments | $135.5 million | $177.4 million |
| Accumulated Deficit | $(937.5) million | $(739.1) million |
| Operating Cash Flow | $(42.71) million | $(48.86) million |
Note: Revenue is derived solely from collaboration agreements. The company has no product sales revenue.
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased by $0.60 million (41%) year-over-year, primarily due to the recognition of deferred revenue from the BMS agreement.
- Reduced R&D Spend: Research and development expenses decreased by $6.46 million to $34.11 million. This was driven by a $3.8 million reduction in research costs (deprioritization of CGD programs) and a $3.7 million decrease in personnel expenses following a workforce reduction in May 2025.
- Increased G&A Spend: General and administrative expenses increased by $4.12 million to $17.41 million. This increase was primarily due to a $5.67 million rise in professional and consultant fees, largely attributed to legal expenses related to ongoing arbitration with Beam Therapeutics.
- Investment Portfolio: Short-term investments decreased from $114.6 million to $71.4 million as the company utilized maturities to fund operations, resulting in a net cash inflow from investing activities of $43.4 million.
Outlook, Risks, and Contingencies
- Going Concern Warning: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for 12 months from the filing date. The company expects to incur operating losses for the foreseeable future and relies on its ability to raise additional capital through equity offerings or collaborations.
- Legal Contingency (Beam Therapeutics): The company is engaged in arbitration with Beam Therapeutics regarding the AATD program. Beam alleges breach of contract and trade secret misappropriation. An adverse ruling could result in monetary damages or an order to cease work on the AATD program and transfer it to Beam.
- Capital Resources: As of March 31, 2026, the company held $135.5 million in cash and short-term investments. Management believes this is sufficient to fund operations into 2027 but may require additional funding sooner depending on strategic decisions and clinical progress.
- Strategic Focus: The company is shifting focus to its in vivo liver franchise (Wilson Disease and AATD), with IND filings targeted for the first and middle halves of 2026, respectively.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $135.5 million cash balance against the burn rate of ~$43 million per quarter to confirm the "into 2027" funding estimate.
- Arbitration Outcome: Monitor the status of the Beam Therapeutics arbitration, as a loss could eliminate the AATD program, a key pillar of the pipeline.
- Capital Raising: Review the status of the "at-the-market" (ATM) offering program and any potential dilutive equity raises required to mitigate the going concern risk.
- Program Deprioritization: Assess the long-term impact of deprioritizing the CGD program on the BMS collaboration revenue stream.
- Regulatory Milestones: Track the timing of IND filings for Wilson Disease and AATD against the stated 2026 targets.